ROR1 and incontinentia pigmenti: Exploring potential therapeutic targets such as ROR1 provides direction for the development of new targeted drugs; designing and developing new antibody-based drugs based on the distinct antigen expression profiles that may exist in different types of IP-LBCL; and facilitating the transport of large molecular drugs across the BBB using carriers like TfR, CD98hc, and exosomes, or by optimizing drug molecular structures and administration methods, can all increase drug concentration and activity in immune-privileged sites.